XML 103 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborative and Other Relationships (Tables)
 12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Co-promotion profit sharing formula Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:
Until GAZYVA First Non-CLL FDA Approval40.0 %
After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date39.0 %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date37.5 %
After Second GAZYVA Threshold Date35.0 %
Pretax profit sharing formula Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:
Until First GAZYVA Threshold Date39.0 %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date37.5 %
After Second GAZYVA Threshold Date35.0 %
Revenues from anti-CD20 therapeutic programs
Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 For the Years Ended December 31,
(In millions)202020192018
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA$1,080.2 $1,542.4 $1,431.9 
Other revenues from anti-CD20 therapeutic programs897.6 748.0 548.3 
Total revenues from anti-CD20 therapeutic programs$1,977.8 $2,290.4 $1,980.2 
Revenues from anti-CD20 therapeutic programs are summarized as follows:
 For the Years Ended December 31,
(In millions)202020192018
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses$1,080.2 $1,542.4 $1,431.9 
Other revenues from anti-CD20 therapeutic programs897.6 748.0 548.3 
Total revenues from anti-CD20 therapeutic programs$1,977.8 $2,290.4 $1,980.2 
Summary of activity related to BAN2401 and Elenbecestat collaboration
A summary of development and sales and marketing expenses related to the BAN2401 Collaboration is as follows:
 For the Years Ended December 31,
(In millions)202020192018
Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat$219.3 $348.7 $232.0 
Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our consolidated statements of income109.6 174.3 116.0 
Total sales and marketing expense incurred by the collaboration9.8 32.4 10.7 
Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income4.9 16.2 5.4 
Summary of activity related to Aducanumab collaboration
A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:
For the Years Ended December 31,
(In millions)202020192018
Total aducanumab development expense$152.0 $179.4 $264.8 
Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income83.6 98.7 234.6 
Total aducanumab sales and marketing expense incurred by the collaboration353.0 27.4 50.6 
Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income193.7 15.1 27.3 
Total aducanumab collaboration third party milestone expense75.0 — — 
Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income33.8 — — 
Summary of activity related to the UCB collaboration A summary of development expense related to the UCB collaboration agreement is as follows:
For the Years Ended December 31,
(In millions)202020192018
Total UCB development expense$58.3 $31.9 $29.7 
Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income29.2 16.0 14.9